Oxurion NV | Small-cap | Healthcare
€0.03
-3.33%
| Oxurion NV Stock Comparison:
Oxurion NV vs Argenx SEOxurion NV vs UCB S.AOxurion NV vs European MedicalOxurion NV vs Celyad Oncology S.AOxurion NV vs Biosenic SAOxurion NV vs BEL 20 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Income Metrics

Balance Sheet Metrics

Total Assets 5.7M
Total Liabilities 16.8M
Shareholders Equity -11.1M

Cash Flow Metrics

Revenue & Profitability Trend

Oxurion NV Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i3.0K263.0K595.0K1.1M2.1M
Cost of Goods Sold i43.0K159.0K513.0K612.0K550.0K
Gross Profit i-40.0K104.0K82.0K516.0K1.5M
Gross Margin % i-1,333.3%39.5%13.8%45.7%73.5%
Operating Expenses
Research & Development i1.4M10.0M16.0M20.7M22.1M
Selling, General & Administrative i2.0M2.7M4.5M4.7M5.5M
Other Operating Expenses i2.0K-600.0K-600.0K-891.0K-694.0K
Total Operating Expenses i3.4M12.1M19.8M24.5M26.9M
Operating Income i382.0K-12.0M-21.9M-27.4M-28.5M
Operating Margin % i12,733.3%-4,555.9%-3,688.4%-2,426.2%-1,371.3%
Non-Operating Items
Interest Income i1.0K2.0K9.0K9.0K21.0K
Interest Expense i14.0K18.0K21.0K26.0K26.0K
Other Non-Operating Income-----
Pre-tax Income i122.0K-19.0M-31.7M-29.6M-28.6M
Income Tax i3.0K3.0K7.0K3.0K0
Effective Tax Rate % i2.5%0.0%0.0%0.0%0.0%
Net Income i119.0K-19.0M-31.7M-29.6M-28.6M
Net Margin % i3,966.7%-7,212.5%-5,326.6%-2,623.7%-1,374.4%
Key Metrics
EBITDA i0-13.5M-21.9M-26.3M-27.2M
EPS (Basic) i€0.09€-114.82€-3,700.00€-7,700.00€-7,315.75
EPS (Diluted) i€0.00€-114.82€-3,700.00€-7,700.00€-7,315.75
Basic Shares Outstanding i1269260165209850138413829
Diluted Shares Outstanding i1269260165209850138413829

Income Statement Trend

Oxurion NV Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i455.0K1.6M3.5M9.7M24.5M
Short-term Investments i-50.0K95.0K247.0K288.0K
Accounts Receivable i13.0K115.0K316.0K81.0K691.0K
Inventory i-05.0K60.0K85.0K
Other Current Assets24.0K60.0K309.0K160.0K237.0K
Total Current Assets i3.6M2.7M7.1M13.4M27.1M
Non-Current Assets
Property, Plant & Equipment i19.0K27.0K110.0K152.0K1.1M
Goodwill i0001.0M2.1M
Intangible Assets i---1.0M2.1M
Long-term Investments-----
Other Non-Current Assets40.0K40.0K40.0K95.0K96.0K
Total Non-Current Assets i2.1M3.8M4.9M5.5M7.2M
Total Assets i5.7M6.6M12.0M18.9M34.3M
Liabilities
Current Liabilities
Accounts Payable i4.5M4.9M5.0M5.0M4.4M
Short-term Debt i11.3M12.2M3.9M3.6M649.0K
Current Portion of Long-term Debt-----
Other Current Liabilities491.0K1.7M2.8M628.0K1.6M
Total Current Liabilities i16.6M19.6M12.3M10.9M7.7M
Non-Current Liabilities
Long-term Debt i8.0K117.0K4.1M8.5M447.0K
Deferred Tax Liabilities i-----
Other Non-Current Liabilities-----
Total Non-Current Liabilities i130.0K129.0K4.2M9.1M1.5M
Total Liabilities i16.8M19.7M16.6M20.0M9.2M
Equity
Common Stock i74.9M73.0M65.4M46.0M44.9M
Retained Earnings i-92.3M-92.4M-73.4M-41.7M-12.6M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i-11.1M-13.2M-4.6M-1.1M25.0M
Key Metrics
Total Debt i11.3M12.3M8.0M12.1M1.1M
Working Capital i-13.0M-16.9M-5.2M2.5M19.4M

Balance Sheet Composition

Oxurion NV Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i119.0K-19.0M-31.7M-29.6M-28.6M
Depreciation & Amortization i-----
Stock-Based Compensation i38.0K316.0K933.0K1.1M458.0K
Working Capital Changes i-2.5M1.6M1.4M-1.7M-946.0K
Operating Cash Flow i-1.5M-14.7M-28.0M-29.5M-29.1M
Investing Activities
Capital Expenditures i33.0K25.0K-41.0K362.0K-84.0K
Acquisitions i-----
Investment Purchases i-----
Investment Sales i-----
Investing Cash Flow i33.0K25.0K-41.0K362.0K-84.0K
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i3.1M12.8M7.2M11.2M0
Debt Repayment i-1.6M-4.5M-3.6M0-
Financing Cash Flow i1.2M8.4M13.9M12.6M0
Free Cash Flow i-2.1M-9.8M-19.4M-27.0M-27.2M
Net Change in Cash i-327.0K-6.3M-14.1M-16.6M-29.2M

Cash Flow Trend

Oxurion NV Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 0.00
Forward P/E -0.06
Price to Sales 510.54
PEG Ratio -0.06

Profitability Ratios

Profit Margin 3,966.67%
Operating Margin 134,650.00%
Return on Equity -1.08%
Return on Assets 3.90%

Financial Health

Current Ratio 0.22
Debt to Equity -1.02
Beta 0.50

Per Share Data

EPS (TTM) €0.00
Book Value per Share €-3.46
Revenue per Share €0.00

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
oxur1.5M0.00--1.08%3,966.67%-1.02
Argenx SE 36.2B33.975.7824.72%41.03%0.71
UCB S.A 35.1B26.903.6214.30%19.45%29.72
European Medical 19.5M35.381.885.40%1.14%191.98
Celyad Oncology S.A 16.2M-0.2232.50-170.92%0.00%177.10
Biosenic SA 1.6M0.00-126.75%-279.17%-1.18

Financial data is updated regularly. All figures are in the company's reporting currency.